LifeVantage (LFVN) Investor presentation summary

Business overview and strategy

• Focuses on wellness and nutrigenomics with patented, science-backed products targeting cellular health and gene activation.

• Operates a direct sales model with 115,000 active consumers in 18 global markets, 70% of revenue from subscriptions.

• Recent acquisition of LoveBiome expands into the microbiome health sector, integrating new products and consultants.

• Launched innovative products like MindBody GLP-1 System and TrueScience Liquid Collagen, addressing major health trends.

• Modernized Evolve Compensation Plan incentivizes consultants through flexible income paths and leadership development.

Financial performance

• Fiscal 2025 revenue reached $228.5 million, with adjusted EBITDA of $22.1 million and adjusted EPS of $0.82.

• Gross margin for FY25 was 80.4%, with an adjusted EBITDA margin of 9.7%.

• Company remains debt-free with $10.2 million in cash and $19.5 million in working capital as of December 31, 2025.

• Returned over $20 million to shareholders since fiscal 2024 via dividends and share repurchases.

• FY26 revenue guidance is $185–200 million, reflecting a strategic focus on sustainable growth.

Market positioning and growth

• Operates in 6 of the 10 largest direct selling markets globally, with 79% of sales from the Americas.

• Addresses high-growth categories: wellness, weight management, and gut health, with global gut health supplement sales projected to reach $32.4 billion by 2035.

• MindBody GLP-1 System targets the expanding GLP-1 market, projected to grow to $88.2 billion by 2032.

• Product innovation and international expansion are key drivers, supported by a robust digital and subscription-based business model.

• Strategic initiatives include new product launches, expanded digital platforms, and enhanced consultant engagement.